Prosecution Insights
Last updated: April 19, 2026
Application No. 18/246,600

RESIN COMPOSITION FOR INJECTION MOLDING AND INJECTION-MOLDED ARTICLE

Non-Final OA §103§112
Filed
Mar 24, 2023
Examiner
FANG, SHANE
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Kaneka Corporation
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
95%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
1136 granted / 1491 resolved
+11.2% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
51 currently pending
Career history
1542
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1491 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION All the references cited in the International Search Report have been considered. None is anticipatory. The most pertinent of these references have been applied below. Election/Restrictions Applicant’s election with traverse of Group I, Claims 1-4 and 6-18 is acknowledged. All groups are distinct inventions and present a serious burden to the U.S. Patent and Trademark Office based on a proper lack of unity analysis. The traversal is on the ground that the restriction is only proper if the claims are independent or distinct and there would be a serious burden placed on the Examiner if restriction is not required. This is not found persuasive because the issue as to the meaning and intent regarding “independent and distinct” as used in 35 U.S.C 121 and 37 CFR 1.41, which is for national applications, but it is not used for PCT national stage (371) applications. For PCT national stage applications, restriction is based upon unity of invention; restriction of a national stage application does not take into account whether or not the inventions are independent or distinct, and does not take into account burden on the examiner. Furthermore, the examiner asserts the special technical feature, the composition of claim 1, is met by prior arts. See below rejections. This restriction is made FINAL. The restriction and election of species as stated in the previous office action are repeated here as such. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim(s) 3, 10-11, and 13 (is)are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims 3 and 10-11 recite “the other hydroxyalkanoate units”. It is unclear whether “the other hydroxyalkanoate units” is referred to: on copolymer A, on copolymer B, or on both copolymer A and copolymer B. For examination purpose, all scenarios are considered. Regarding claim 13, the limitation "preferably” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-4 and 6-18 is (are) rejected under 35 U.S.C. 103 as being unpatentable over Whitehouse et al. (US 20100305280). As to claims 1, 3-4, and 6-7, Whitehouse (abs., claims, examples) discloses a resin composition for injection molding (90, claim 5) comprising (Table 2-4, 180-187, Ex.2-4, ref.8) 35 parts of Talc (a layered clay mineral) by 100 parts of the total polyhydroxyalkanoate (PHA) and a blend comprising of poly(3-hydroxybutyrate) (PHB) and poly(3-hydroxybutyrate)-co-11%-4-hydroxybutyrate). Whitehouse (16-18, 88-90, 180) further discloses PHB/poly(3-hydroxybutyrate)-co-11%-4-hydroxyhexanoate) (blends 2-4) and poly(3-hydroxybutyrate)-co-6%-3-hydroxyhexanoate) (78 wt%)/poly(3-hydroxybutyrate)-co-33%-4-hydroxybutyrate) (22 wt%) (blend 8) are functionally equivalent PHA blends for producing relatively flexible and high melting blends of PHA for injection molding. The aforementioned % is referred as wt% (18). Therefore, it would have been obvious to one of ordinary skill in the art to have replaced blends 2-4 with blend 8 because of their equivalent functionality as primary PHA blends for producing relatively flexible and high melting blends of PHA for injection molding. These conditions appear to equally apply to both productions using similar PHA blends. This adaptation would have obviously yielded instantly claimed composition of claims 1, 3-4, and 6-7. As to the claimed mol% of other hydroxyalkanoate units of the claimed copolymer (A) in claims 1 and 6, the aforementioned poly(3-hydroxybutyrate)-co-6%-3-hydroxyhexanoate has a 5 mol% of 3-hydroxyhexanoate by the following calculation: PNG media_image1.png 200 400 media_image1.png Greyscale As to the claimed mol% of other hydroxyalkanoate units of the claimed copolymer (B) in claims 1 and 7, the aforementioned poly(3-hydroxybutyrate)-co-33%-4- hydroxybutyrate) has a 33 mol% of 4- hydroxybutyrate (identical MW of the isomeric monomers). As to claims 2 and 10-11, blend 8 (poly(3-hydroxybutyrate)-co-6%-3-hydroxyhexanoate) (78 wt%)/poly(3-hydroxybutyrate)-co-33%-4-hydroxybutyrate) (22 wt%)) has a total 11 mol% (falling within the claimed ranges of claim 2) of other hydroxyalkanoate units and a mol% ratio of 89:11 (falling within the claimed ranges of claims 10-11) by the following calculation: PNG media_image2.png 200 400 media_image2.png Greyscale As to claims 8-9, poly(3-hydroxybutyrate)-co-6%-3-hydroxyhexanoate) in the blends is 78 wt%, and poly(3-hydroxybutyrate)-co-33%-4- hydroxybutyrate) in the blends is 22 wt%. As to claims 12-13, the Mw of both PHAs in the blends (22-25, 119-120, Table 2) can both be 750k, so the resultant blend would have a Mw of 750k, falling within the claimed range. As to claims 16-17, the loading of talc is 35 parts of 100 parts of PHA, falling within the claimed range. As to claim 18, Whitehouse (claim 4, 117) discloses the composition may comprise a third PHA at most about 20 wt%, overlapping with the claimed range. It has been found that where claimed ranges overlap ranges disclosed by the prior art, a prima facie case of obviousness exists - see MPEP 2144.05. The PHA can be derived from biomass (157), the same biomass component used as dispersion acid according to instant pgpub [0058]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the aforementioned composition and added at most about 20 wt% biomass based PHA, because the resultant composition would yield improved environmental friendliness. Claim(s) 14-15 is (are) rejected under 35 U.S.C. 103(a) as being unpatentable over Whitehouse et al. (US 20100305280) in view of Koyama et al. (US 20160251494) listed on IDS and ISR. Disclosure of Whitehouse is adequately set forth in ¶1 and is incorporated herein by reference. Whitehouse is silent on the claimed particle size. In the same area of endeavor of producing molds comprising PHA and talc (abs., examples 1 and 6-7, claims, Table 1), Koyama (70) discloses an optimal size range of talc of 0.1-50 microns (overlapping with the range of claim 15) to obtain balanced handleability and impact resistance. It has been found that where claimed ranges overlap ranges disclosed by the prior art, a prima facie case of obviousness exists - see MPEP 2144.05. Therefore, as to claims 14-15, it would have been obvious to one of ordinary skill in the art to have modified the aforementioned Whitehouse’s composition and replaced the talc with the aforementioned talc (0.1-50 microns) of Koyama, because the resultant composition would yield improved and balanced handleability and impact resistance. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHANE FANG whose telephone number is (571)270-7378. The examiner can normally be reached on Mon-Thurs. 8am-6pm. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached on 571.572.1302. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHANE FANG/Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

Mar 24, 2023
Application Filed
Jan 24, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600818
PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS
2y 5m to grant Granted Apr 14, 2026
Patent 12595395
KIT-OF-PARTS FOR CURABLE POLYASPARTIC ACID ESTER-BASED COATING COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595338
PROCESS FOR PREPARING A HYDROXY GROUP FUNCTIONALIZED THIOETHER
2y 5m to grant Granted Apr 07, 2026
Patent 12577411
GAS-BARRIER COATING COMPOSITION AND GAS-BARRIER LAMINATE
2y 5m to grant Granted Mar 17, 2026
Patent 12581846
ELECTROLUMINESCENT POLYMER BASED ON PHENANTHROIMIDAZOLE UNITS, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
95%
With Interview (+19.0%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1491 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month